MX369148B - Agentes de unión kir3dl2. - Google Patents
Agentes de unión kir3dl2.Info
- Publication number
- MX369148B MX369148B MX2015003476A MX2015003476A MX369148B MX 369148 B MX369148 B MX 369148B MX 2015003476 A MX2015003476 A MX 2015003476A MX 2015003476 A MX2015003476 A MX 2015003476A MX 369148 B MX369148 B MX 369148B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- binding agents
- kir3dl2 binding
- derivatives
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702834P | 2012-09-19 | 2012-09-19 | |
| PCT/EP2013/069302 WO2014044686A1 (en) | 2012-09-19 | 2013-09-17 | Kir3dl2 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003476A MX2015003476A (es) | 2015-08-10 |
| MX369148B true MX369148B (es) | 2019-10-30 |
Family
ID=49226157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003476A MX369148B (es) | 2012-09-19 | 2013-09-17 | Agentes de unión kir3dl2. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10577419B2 (https=) |
| EP (1) | EP2897980B1 (https=) |
| JP (1) | JP6507097B2 (https=) |
| CN (1) | CN104640880B (https=) |
| AU (1) | AU2013320360B2 (https=) |
| BR (1) | BR112015006060B1 (https=) |
| CA (1) | CA2881765C (https=) |
| DK (1) | DK2897980T3 (https=) |
| ES (1) | ES2770399T3 (https=) |
| IL (1) | IL237220B (https=) |
| MX (1) | MX369148B (https=) |
| RU (1) | RU2682449C2 (https=) |
| WO (1) | WO2014044686A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539045T3 (es) * | 2009-01-19 | 2015-06-25 | Innate Pharma | Anticuerpos anti-KIR3D |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| DK2958941T3 (da) | 2013-02-20 | 2019-06-24 | Innate Pharma | Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom |
| US10280222B2 (en) * | 2014-03-14 | 2019-05-07 | Innate Pharma | Humanized antibodies with increased stability |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| CA2952532A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
| WO2016030488A1 (en) * | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| CA2988912C (en) | 2015-06-10 | 2023-09-12 | National Research Council Of Canada | Carbonic anhydrase ix-specific antibodies and uses thereof |
| DK3313876T3 (da) | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| WO2016207278A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| WO2017156423A2 (en) * | 2016-03-11 | 2017-09-14 | Integrated Biotherapeutics, Inc. | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever |
| US10858431B2 (en) * | 2016-06-30 | 2020-12-08 | Trellis Bioscience, Llc | Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling |
| US20190248895A1 (en) * | 2016-10-21 | 2019-08-15 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| WO2018115262A1 (en) | 2016-12-23 | 2018-06-28 | Innate Pharma | Heterodimeric antigen binding proteins |
| EP3579879A4 (en) * | 2017-02-09 | 2020-12-16 | Memorial Sloan Kettering Cancer Center | ANTI-BODY ANTI-KIR3DL1 |
| EP3630182A4 (en) * | 2017-05-24 | 2021-02-24 | Development Center for Biotechnology | HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT |
| JP7264831B2 (ja) * | 2017-06-15 | 2023-04-25 | ディベロップメント センター フォー バイオテクノロジー | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 |
| TWI789399B (zh) * | 2017-06-22 | 2023-01-11 | 財團法人生物技術開發中心 | 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途 |
| AU2018371114A1 (en) | 2017-11-21 | 2020-05-07 | Innate Pharma | Multispecific antigen binding proteins |
| US11560421B2 (en) * | 2018-02-09 | 2023-01-24 | Osaka University | Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| CA3125945A1 (en) | 2019-01-22 | 2020-07-30 | Innate Pharma | Treatment of t cell lymphoma |
| CN114867493B (zh) | 2019-10-04 | 2026-04-10 | 阿尔伯特爱因斯坦医学院 | Kir3dl3是免疫系统的抑制性受体及其用途 |
| CN110950960B (zh) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 |
| US20230119066A1 (en) * | 2020-03-23 | 2023-04-20 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
| CN113817052A (zh) * | 2020-06-19 | 2021-12-21 | 南京金斯瑞生物科技有限公司 | 抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| JP2024513880A (ja) | 2021-04-05 | 2024-03-27 | イナート・ファルマ・ソシエテ・アノニム | 免疫組織化学法およびｋｉｒ３ｄｌ２特異的薬剤 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| US20250002601A1 (en) | 2021-06-09 | 2025-01-02 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
| CN113248609B (zh) * | 2021-07-14 | 2021-09-10 | 深圳市盛波尔生命科学技术有限责任公司 | 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒 |
| WO2023009759A2 (en) * | 2021-07-30 | 2023-02-02 | R.P. Scherer Technologies, Llc | Antibody-drug conjugates and methods of use thereof |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| AU2023342647A1 (en) | 2022-09-15 | 2025-02-20 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| CN117801108B (zh) * | 2023-12-06 | 2024-06-07 | 无锡傲锐东源生物科技有限公司 | 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191137A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of trop2-specific antigen binding proteins and cytokines |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025245386A1 (en) * | 2024-05-23 | 2025-11-27 | La Jolla Institute For Immunology | Kir3dl2 as an anti-cancer target |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002050122A2 (en) | 2000-12-18 | 2002-06-27 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Means for the diagnosis and therapy of ctcl |
| ES2393485T3 (es) * | 2003-07-02 | 2012-12-21 | Innate Pharma | Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia |
| ES2539045T3 (es) | 2009-01-19 | 2015-06-25 | Innate Pharma | Anticuerpos anti-KIR3D |
| WO2011027310A1 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| US20130315933A1 (en) * | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| CA2881764C (en) | 2012-09-19 | 2022-08-16 | Innate Pharma | Kir3dl2 binding agents |
| DK2958941T3 (da) | 2013-02-20 | 2019-06-24 | Innate Pharma | Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom |
| US20160130346A1 (en) * | 2013-05-29 | 2016-05-12 | Institut National De La Sante Et De La Recherche Medicale | Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas |
| US10280222B2 (en) | 2014-03-14 | 2019-05-07 | Innate Pharma | Humanized antibodies with increased stability |
| US20190248895A1 (en) | 2016-10-21 | 2019-08-15 | Innate Pharma | Treatment with anti-kir3dl2 agents |
-
2013
- 2013-09-17 RU RU2015104760A patent/RU2682449C2/ru active
- 2013-09-17 ES ES13765703T patent/ES2770399T3/es active Active
- 2013-09-17 BR BR112015006060-9A patent/BR112015006060B1/pt active IP Right Grant
- 2013-09-17 WO PCT/EP2013/069302 patent/WO2014044686A1/en not_active Ceased
- 2013-09-17 CN CN201380048468.1A patent/CN104640880B/zh active Active
- 2013-09-17 DK DK13765703.7T patent/DK2897980T3/da active
- 2013-09-17 CA CA2881765A patent/CA2881765C/en active Active
- 2013-09-17 EP EP13765703.7A patent/EP2897980B1/en active Active
- 2013-09-17 MX MX2015003476A patent/MX369148B/es active IP Right Grant
- 2013-09-17 AU AU2013320360A patent/AU2013320360B2/en active Active
- 2013-09-17 JP JP2015532387A patent/JP6507097B2/ja active Active
-
2015
- 2015-02-12 IL IL237220A patent/IL237220B/en active IP Right Grant
- 2015-03-19 US US14/662,349 patent/US10577419B2/en active Active
-
2020
- 2020-02-28 US US16/804,018 patent/US11858990B2/en active Active
-
2023
- 2023-12-27 US US18/396,776 patent/US20240124579A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK2897980T3 (da) | 2020-02-17 |
| BR112015006060B1 (pt) | 2023-03-21 |
| AU2013320360B2 (en) | 2018-06-14 |
| US20200199228A1 (en) | 2020-06-25 |
| CA2881765A1 (en) | 2014-03-27 |
| BR112015006060A2 (pt) | 2018-09-25 |
| US20150232556A1 (en) | 2015-08-20 |
| CN104640880A (zh) | 2015-05-20 |
| MX2015003476A (es) | 2015-08-10 |
| RU2682449C2 (ru) | 2019-03-19 |
| JP2015535820A (ja) | 2015-12-17 |
| JP6507097B2 (ja) | 2019-04-24 |
| EP2897980B1 (en) | 2019-11-06 |
| CA2881765C (en) | 2024-02-13 |
| AU2013320360A1 (en) | 2015-03-05 |
| CN104640880B (zh) | 2020-06-09 |
| ES2770399T3 (es) | 2020-07-01 |
| IL237220A0 (en) | 2015-04-30 |
| US11858990B2 (en) | 2024-01-02 |
| WO2014044686A1 (en) | 2014-03-27 |
| RU2015104760A (ru) | 2016-11-10 |
| EP2897980A1 (en) | 2015-07-29 |
| IL237220B (en) | 2020-02-27 |
| US20240124579A1 (en) | 2024-04-18 |
| US10577419B2 (en) | 2020-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX369148B (es) | Agentes de unión kir3dl2. | |
| IN2014KN00848A (https=) | ||
| WO2014160160A3 (en) | Antibody drug conjugates and corresponding antibodies | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| WO2011004028A3 (en) | Tlr3 binding agents | |
| WO2014163714A3 (en) | Antibody drug conjugates | |
| EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| PH12012500828A1 (en) | Compositions and methods for treating inflammatory disorders | |
| MX360163B (es) | Moleculas de union il-6. | |
| TN2015000277A1 (en) | Bmp-6 antibodies | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| EP2596365A4 (en) | MONOCLONAL ANTIBODIES TO PCBP1 ANTIGENES AND APPLICATIONS THEREOF | |
| HK1196856A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |